Imatinib-d3 (hydrochloride)

Imatinib-d3 (hydrochloride)

• CAS Number: 1134803-18-1
• UNSPSC Description: Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
• Target Antigen: Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Autophagy;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Purity: 95.19
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=CC=C(C=C1)CN2CCN(CC2)C([2H])([2H])[2H])NC3=CC=C(C)C(NC4=NC=CC(C5=CN=CC=C5)=N4)=C3
• Molecular Weight: 496.62
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.|[3]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported